Injectable Contraceptives Market - Industry Analysis and Forecast (2025-2032) by Component, Water Depth and Region

Injectable Contraceptives Market Overview

 

Injectables are one of the world's most popular modern methods of contraception: These are safe for use they last for a rather long time, are more effective than regular contraceptives, and can be administered secretly. The injection contains a hormone commonly known as depot medroxyprogesterone acetate (DMPA); this is a substance related to the hormone progesterone. Pregnancy control through the injections has to be administered every 3 months to be effective. Globally, injectable contraceptives are the most widely used modern method of fertility control after female sterilization, IUDs, and OPs in the Injectable Contraceptives Market. DMPA is a 3-month injectable contraceptive that acts on the mechanism of ovulation inhibition through inhibition of LH brain waves. DMPA is likely to cause temporarily low BMD which returns to normal once the contraceptive is stopped. There are non-United States versions of combined injectable contraceptives. Other officially recommended injectable contraceptives include norethindrone enanthate (NET-EN) as well as contraceptives that contain a progestogen (MPA or NET-EN) and an estrogen (estradiol cypionate or valerate or enanthate) Injectable contraceptives are used in different countries of the world.

 

An estimated 16 million women throughout the world are currently relying on injectable steroids for contraception in the Injectable Contraceptives Market. The choice of injectable methods includes products effective for 3 months, 2 months, or 1 month. Although little known in Europe, these methods represent the third most prevalent form of reversible contraception worldwide. Trend estimates suggest that this number is rising, due to the reassuring World Health Organization (WHO) data regarding cancer risk, and the recent approval of the 3-monthly injectable depo medroxyprogesterone acetate (DMPA, or Depo-Provera) by the United States Federal Drug Administration (USFDA). Furthermore, some injectables can be used by women who cannot use methods that contain estrogen, including breastfeeding women. In some cultures, injectable contraceptives are favored over other methods because they can be used without the knowledge of family and friends. The contraceptive injection is most frequently used by Women who are younger and have lower incomes.

 

 

To get more Insights: Request Free Sample Report

 

Table 1. Formulation, Injection Schedule, and Availability of Injectable Contraceptives

Formulation	Developer	Brand Name/Manufacturer	Injection Schedule	Availability
Progestin only: 150 mg depot medroxyprogesterone acetate (DMPA)	The Upjohn Company	Depo-Provera/Upjohn Megestron/Organon	Every 3 months, 12 weeks, or 90 days	Registered in over 100 countries; available in both public and private sectors.
Progestin only: 200 mg norethindrone (norethisterone) enanthate (NET EN)	Schering AG	Noristerata/Schering AG Doryxus/ Richter Gedeon Ltd.	Every 2 months	Registered in over 60 countries; available in both public and private sectors.
Progestin + Estrogen: 25 mg DMPA + 5 mg estradiol cypionate	Upjohn, WHO	Cyclofem, Cyclofemina, Novafem/Aplicaciones Pharmaceuticals (Mexico), PT Tunggal (Indonesia), Lunelle/Upjohn (US) Cyclogeston/ PT Triyasa Nagamas Farma (Indonesia)	Every month	Registered in 18 countries; available in both public and private sectors.
Progestin + Estrogen: 50 mg NET EN + 5 mg estradiol valerate	WHO	mesigyna, Norigynon/ Schering AG	Every month	Registered in 35 countries.
Progestin + Estrogen: 150 mg Dihydroxy Progesterone Acetophenide + 10 mg estradiol enanthate	Squibb Pharmaceutical Company	Perlutan, Topasel, Agurin Horprotal, Uno-Ciclo/ Various manufacturers in Latin America	Every month	Available in pharmacies in many Latin American countries and Spain; generally, not available in public family planning programs.
Half-dose: 75 mg Dihydroxy Progesterone Acetophenide + 5 mg estradiol enanthate		Anafertin, Yectames/ Various manufacturers in Latin America	Every month	Latin America
Progestin + Estrogen: 250 mg 17µ -hydroxy-progesterone Caproate + 5 mg estradiol valerate	Chinese researchers; Squibb Pharmaceutical Company	Chinese Injectable No. 1	Every month, 2 injections in the first month	China

 

Advantages, Disadvantages of using Injectable Contraceptives Market

 

 

Injectable Contraceptives Market Recent Development

 

• A 2023 Contraception study reports that there was a significant increase in the provision of DMPA-SC for self-injection during this time, although this is still a small portion of the overall use of DMPA-SC.

 

• In 2023, The Indian Council of Medical Research (ICMR) completed the clinical trials of the world's first injectable male contraceptive which showed that it is safe and highly efficacious without any serious side effects. The findings of the phase-III clinical trial, which involved 303 candidates aged 25-40 years, were published in the international open-access Andrology journal.

 

• In 2023, UNFPA aided Kenya's Ministry of Health in expanding family planning services, distributing various methods to over 6,000 health facilities in 47 counties, benefiting over 2.5 million women. The recently handed-over DMPA-SC contraceptives will be distributed through KEMSA, benefiting over 400,000 women, and are expected to prevent 42,750 unintended pregnancies and 122 maternal deaths.

 

Injectable Contraceptives Market Trend

 

In the world, the female population of childbearing age, that is, from 15-49 years increased to 1. Already from $3 billion in 1990, the level of direct investments of foreigners in the USA has decreased to a level of $1. To $9 billion in 2021, 46 percent up from 2020, according to the United Nations. One of the most effective ways of Minimizing cases of unwanted pregnancies is practicing contraception, this is the act of deliberately controlling the number of children and space between the children a woman and or a couple wants to have. Technology Adoption and Dependency Modern techniques in the feasibilities of injective contraceptives intend to rise in the coming years and the use of Injectable Contraceptives Market is also going to enhance shortly.

 

 

Community pharmacies in Kenya offer the “last mile” of family planning services in the form of injectable contraceptives to those who otherwise cannot access this and some related services (Pharmaceutical Society of Kenya, Personal communication). DeepRoot-USAID, for the Global Health Supply Chain Program- Procurement and Supply Chain Management, engaged IQVIA Government Solutions to provide economics on the structure that will enable the establishment of an injectable and oral contraceptive manufacturing facility in SSA, alongside a model that estimates the cost of construction, operating expenditure and further, how corporation tax and depreciation will affect the Injectable Contraceptives Market and how large the future market will be and the corresponding

 

The global number of women of reproductive age (15-49 years) who use modern and traditional contraceptive methods and who have unmet needs or no need for family planning, 2021 (million UD dollars)

 

 

Injectable Contraceptives Market Dynamics

 

Injectable Contraceptives Market Drivers

 

Rise in awareness about family planning & Initiatives by government and other organizations to increase access to injectable contraceptives

 

Enhancing the knowledge of family planning is an important reason for the demand for injectable contraceptives. The governments of many countries are thus adopting family planning services to create awareness of contraceptive measures among the population, injectables included. For example, World Family Planning 2022 contains facts and Figures on global Family planning, rules over contraceptives, unmet need for family planning, and advancement toward the family planning agenda of SDGs. According to the report, there is a gradual rise in the number of women in the world practicing contraception and this includes many who preferred injectable contraceptives. Since the social and cultural acceptance of family planning increases, women prefer injectables as they are easy to use and efficient. In 2022, approximately 1. 2 billion women in the world relied on contraceptives and the injection was quite common in many areas of the world. It has been reported by the organization that unintended pregnancies persist as 257 million women want to prevent pregnancies yet they are not using modern methods of contraception. Therefore, fulfillment of this need can greatly contribute to an expansion of the Injectable Contraceptives Market for injectables by enabling more women to use the method of contraception that would protect them in the long run.

 

Increasing awareness about the benefits of injectable contraceptives

 

One of the major trends that is acting as the driver for the Injectable Contraceptives Market is the increasing knowledge about injectable contraceptives. Depo-Provera is a type of injectable contraceptive commonly associated with high efficacy regarding pregnancy prevention. They work for up to 3 months after one administration, this is more flexible than the daily pills. According to the World Health Organization (WHO), injectable contraceptives are the third most popular contraceptive method globally, following female sterilization and intrauterine devices (IUDs). Injectables are convenient for women who prefer not to take a daily pill. They require administration only once every three months, enhancing compliance and reducing the likelihood of missed doses. In countries like Uganda and Ethiopia, a significant proportion of women use injectables due to their convenience. For instance, in Uganda, approximately 30% of modern contraceptive users choose injectables.

 

Injectable Contraceptives Market Challenges

 

Misconceptions about Injectable Contraceptives

Covenant Women Watch, Health Global, and some human rights organizations have however rejected the use of injectable contraceptives in the national program because of some fears they have regarding side effects that are associated with this method as well as because of possible abuse. Another popular issue of discussion was the issue of lesser bone mineral density level that is expected in cases of use of DMPA use by adolescent and perimenopausal females. Perceptions about injectable contraceptives vary widely by region in the Injectable Contraceptives Market about Injectable Contraceptives.

 

To increase sales of the company, Companies can educate and increase awareness about the product among the consumers in the Injectable Contraceptives Market. People generally have misconceptions related to Infertility., increasing cancer risks, building up of menstrual blood during amenorrhea, and transmission of diseases. Companies can run brand awareness campaigns, and conduct talk sessions educating about the product, benefits, usage, dosage, precautions, etc. The Indian Council on Medical Research (ICMR) has cleared all these doubts, and the Drugs Controller General of India has to submit another report. The opposition to including DMPA in India’s family planning program is based on decades-old data and disproven hypotheses. The debate about the capacity of public-sector facilities to provide injectables without compromising quality seriously underestimates the ability of a system that is capable of providing millions of sterilizations annually.

 

Injectable Contraceptives Market   Segment Analysis

 

Based on Components,

The injectable contraceptives market is divided into progesterone-only injectables and combined injectable contraceptives. The progestogen-only injectable contraceptives are depot medroxyprogesterone acetate and norethisterone enanthate contraceptives. This segment is fast growing because of the effectiveness and reliability of this method in averting pregnancies. Furthermore, this contraceptive type suits individuals who cannot take estrogen-based contraceptives and has the advantage of less frequent injections because they are administered after three months or four times per year. Typically, Depo-Provera has been known to play about 4% effectorial rate per year in other words, it is 96% efficient in averting pregnancy among users. The market share statistics of today show that by 2021, Depo-Provera controlled about 60% of the global phase III progesterone-only injectable contraceptives market hence its preference.

 

Based on Age Group,

 

The Injectable Contraceptives Market is segmented by age group: age groups include 15-24 years, 25-34 years, 35-44 years and above 44 years. Currently, the 15-24 years age group has the highest market share, and based on this research, it is anticipated to portray the highest CAGR throughout the forecast tenure. This growth is driven by the convenience of injections administered every few months, which appeals to young adults balancing education, careers, and social activities. Furthermore, the high effectiveness of injectable contraceptives offers reassurance against unintended pregnancies for individuals not yet ready for parenthood. Privacy and discretion are additional benefits that enable young adults to manage their reproductive health confidentially, contributing significantly to the segment's expansion and overall market growth.

 

Number of women of reproductive age (15-49 years) using various contraceptive methods, world, 2022 (millions and percentage)

 

 

Based on Duration of Action,

 

In 2024, the Injectable Contraceptives Market is divided into short-acting and long-acting categories based on the duration of action. Short-acting injectable contraceptives led in market revenue and are projected to expand further. This growth is driven by their convenient administration, appealing to those preferring reliable birth control without a long-term commitment. According to a WHO study, 90% of users favor the three-month interval injections over daily or monthly contraceptive methods. World Health Organization (WHO): Studies and reports on contraceptive methods and user preferences, including interval administration of injectable contraceptives. Moreover, short-acting injectables are ideal for individuals prioritizing minimal disruption to their daily routine and privacy, as they can receive injections discreetly. The manageable dosing interval ensures consistent usage, appealing to those who prefer not to commit to a daily regimen. These factors directly contribute to the segment's growth in the market.

 

Injectable Contraceptives Market   Regional Insights

 

The market of injectable contraceptives in 2024 is bestowed by geographical regions of North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America came out on top, owing to improved structures within the health sectors that guarantee a high number of women availing different contraceptives such as injectables. The region emphasizes the health education of reproductive health and family planning that assists the knowledge of the individuals in appropriating the correct contraceptives to use. For example, several modified sex education in schools and Anti-AIDS clinics help make more people aware of such diseases and conditions. Additionally, the presence of trained medical professionals ensures precise administration and monitoring of injectable contraceptives, bolstering their reliability and contributing to Injectable Contraceptives Market growth in North America.

 

The United States, a key market in North America, benefits from the Affordable Care Act (ACA), which mandates insurance coverage for contraceptives, including injectables in the Injectable Contraceptives Market. This policy has expanded access for women cutting across all the classes of society. Other centers that offer reproductive health services include Planned Parenthood in the U. S offering services such as counseling on contraceptives including injectables. They stress the importance of educating and involving patients and, to an extent, increasing patients’ autonomy. This figure was retrieved from the Guttmacher Institute, an organization that specializes in research on sexual and reproductive health and rights, according to them, approximately 10. Recent statistics show 6 million women in the U. S. relax and resort to injectable contraceptives. According to PPFA, contraceptive injections rank among the most commonly used methods to prevent pregnancy by the clients indicating their popularity. The consumption of DMPA in India has been on the rise with an annual compounded increase of 25-30 percent. One million vials were sold last year. The product is widely available in India through private and social marketing channels and is being used by women across the country.

 

Contraceptive use (modern and traditional) and unmet need for family planning among women with a need for family planning, world and by region, 2021 (percentage)

 

 

Injectable Contraceptives Market   Scope

 

Injectable Contraceptives Market Scope
Market Size in 2024	USD 366.17 Mn.
Market Size in 2032	USD 497.29 Mn.
CAGR (2025  - 2032)	3.9%
Historic Data	2019-2024
Base Year	2024
Forecast Period	2025-2032
Segments Analysis	By Type Progesterone-only Injectables Depot medroxyprogesterone acetate Norethisterone enanthate Combined injectable contraceptives
	By Age Group 15-24 Years 25-34 Years 35–44 years Above 44 years
	By Route Intramuscular Subcutaneous
	By Duration of Action Short-acting Injectable Contraceptives Long-acting injectable contraceptives
	By End-User Hospital Gynecology clinics Other end-users
Regional Scope	North America (United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Russia, Austria, and Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC Middle East and Africa ( South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America

 

Injectable Contraceptives Market Key players

 

North America

1. Pfizer Inc. (USA)
2. Merck & Co., Inc. (USA)
3. Amphastar Pharmaeceutical Inc.(USA)
4. Mylan Labs Ltd. (USA)
5. Johnson & Johnson (USA)

Europe

1. Bayer Plc (Germany)

Asia Pacific

1. Zhejiang xianju Pharmaceutical co., ltd. (China)
2. Eugia Pharma (India)
3. PT Tunggal (Indonesia)
4. Incepta Pharmaceuticals (Bangladesh)
5. Lupin Pharmaceuticals, Inc. (India)
6. Sun Pharmaceutical Industries Ltd. (India)

Middle East and Africa (MEA)

1. Teva Pharma (Israel)